Filing Details

Accession Number:
0001399529-20-000072
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-10-19 21:59:16
Reporting Period:
2020-10-15
Accepted Time:
2020-10-19 21:59:16
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1399529 Dicerna Pharmaceuticals Inc DRNA Pharmaceutical Preparations (2834) 205993609
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1598480 B James Weissman C/O Dicerna Pharmaceuticals, Inc.
33 Hayden Avenue
Lexington MA 02421
Chief Operating Officer & Evp No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-10-15 8,720 $3.42 30,580 No 4 M Direct
Common Stock Disposition 2020-10-15 8,720 $20.20 21,860 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (Right to Buy) Disposition 2020-10-15 8,720 $0.00 8,720 $3.42
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
8,720 2023-09-24 No 4 M Direct
Footnotes
  1. The Reporting Person sold an aggregate of 8,720 shares of common stock on October 15, 2020 (the "Shares Sold") as reported in this Form 4. The Shares Sold represent 1.16% of 752,878 shares of common stock, which is the number of shares of common stock owned by the Reporting Person prior to the Shares Sold transaction reported in this Form 4, as well as shares issuable upon exercise or settlement of vested and unvested options and restricted stock units held by the Reporting Person as of the date of this report.
  2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 25, 2019.
  3. The vesting of this option was subject to achievement of pre-established performance goals. As of the transaction date, the options were fully vested.